Authors:
Pan, LC
Carpino, PA
Lefker, BA
Ragan, JA
Toler, SM
Pettersen, JC
Nettleton, DO
Ng, O
Pirie, CM
Chidsey-Frink, K
Lu, BH
Nickerson, DF
Tess, DA
Mullins, MA
MacLean, DB
DaSilva-Jardine, PA
Thompson, DD
Citation: Lc. Pan et al., Preclinical pharmacology of CP-424,391, an orally active pyrazolidinone-piperidine growth hormone secretagogue (vol 14, pg 121, 2001), ENDOCRINE, 14(3), 2001, pp. 437-437
Citation: Lc. Pan, Preclinical pharmacology of CP-424,391, an orally active pyrazolidinone-piperidine growth hormone secretagogue, ENDOCRINE, 14(1), 2001, pp. 121-132
Authors:
King, MK
Gay, DM
Pan, LC
McElmurray, JH
Hendrick, JW
Pirie, C
Morrison, A
Ding, C
Mukherjee, R
Spinale, FG
Citation: Mk. King et al., Treatment with a growth hormone secretagogue in a model of developing heart failure - Effects on ventricular and myocyte function, CIRCULATION, 103(2), 2001, pp. 308-313
Authors:
Smock, SL
Pan, LC
Castleberry, TA
Lu, BH
Mather, RJ
Owen, TA
Citation: Sl. Smock et al., Cloning, structural characterization, and chromosomal localization of the gene encoding the human prostaglandin E-2 receptor EP2 subtype, GENE, 237(2), 1999, pp. 393-402
Citation: Wv. Houck et al., Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure, CIRCULATION, 100(19), 1999, pp. 2003-2009
Citation: Wr. Bowen et al., Predicting equilibrium constants for ion exchange of proteins - a colloid science approach, COLL SURF A, 143(1), 1998, pp. 117-131